Agentix Corp. (AGTX) Research

Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.

Market snapshot

Symbol
AGTX
Price
$0.02
Day change
0.00%
Market cap
$681.1K
P/E ratio
-1.15x
52-week range
0.0164-0.055
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Algernon Pharmaceuticals Inc. (AGNPF)
  • Appili Therapeutics Inc. (APLIF)
  • Strainsforpains, Inc. (EBYH)
  • Galera Therapeutics, Inc. (GRTX)
  • Health Sciences Group, Inc. (HESG)
  • Universal Ibogaine Inc. (IBOGF)
  • Medigene AG (MDGEF)
  • Neon Bloom, Inc. (NBCO)

Recent insider activity

  • Puzzo Thomas E — trade (0 shares) on 2020-03-29
  • Grays Peak Ventures LLC — P-Purchase (767000 shares) on 2020-03-29
  • Grays Peak Ventures LLC — J-Other (1407000 shares) on 2020-02-24
  • Winterhalter Michael — P-Purchase (150000 shares) on 2020-03-29
  • Winterhalter Michael — S-Sale (10015 shares) on 2019-11-22

Open Agentix Corp. (AGTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.